Kornimate/medical-research-clean huggingface dataset:
evaluation of s-adenosyl methionine (sam-e) for recurrent abdominal pain in children

Conditions: Abdominal Pain

Summary: this pilot study will investigate the efficacy of sam-e for the treatment of recurrent abdominal pain in children. this will be an open-labeled study and all participants will receive sam-e therapy. given that sam-e has been demonstrated to improve symptoms of depression and pain with minimal side effects as compared to other antidepressant therapy, we hypothesize that sam-e will reduce pain symptoms among children with recurrent abdominal pain.


Eligibility criteria:
inclusion criteria: * 8 to 22 years old * diagnosed with rap as verified by a physician, and having at least twice weekly episodes of abdominal pain which cause the patient to withdraw from normal activities. * at least one month trial on a high fiber diet without resolution of abdominal pain. * ambulatory exclusion criteria: * focal abdominal pain by history or physical exam, unless a negative (including endoscopic) evaluation has been performed * current diagnosis of inflammatory bowel disease, pancreatitis (acute or recurrent), peptic ulcer disease, gastrointestinal infection (unresolved), or ongoing gastrointestinal inflammation. * current or recent (within the past year) pregnancy and/or current breastfeeding. * current diagnosis of nephropathy or genitourinary disease. * blood in stools or emesis (exception: blood in the stool secondary to hemorrhoids is not an exclusion criterion). * unintentional loss of over 10% body weight over the past 3 months or weight \< 100% ideal body weight. * recurrent fevers (t\>100f) at least once a week or with abdominal pain episodes. * recurrent dehydration with abdominal pain episodes requiring intravenous rehydration. * current personal diagnosis of depression or report of suicidality, mania or bipolar disorder. * family history of mania or bipolar disorder. * current use of opiates or other prescription pain medications and/or refusal to remain off opiate/prescription pain medications during the study period. * currently receiving additional therapies besides diet for recurrent abdominal pain and/or refusal to remain off such therapies during the study period, including but not limited to anticholinergic medications, antidepressant medications, biofeedback therapy, cognitive behavioral therapy. * hypersensitivity to sam-e. * inability of child to provide assent and/or inability of parent/custodian to give consent.

Keywords: abdominal pain children
self-care management in chronic disease

Conditions: Disease Self Management

Summary: self-management of chronic diseases includes treatment and adoption of healthy behaviors. the research was planned to determine the effect of health education on disease management in the elderly with chronic diseases. the research will be conducted in a parallel group, randomized controlled manner. older adults will receive 6 weeks of health education. after the training, the scales will be re-administered face to face or online.


Eligibility criteria:
inclusion criteria: * being in the 65-75 age group, * having a chronic disease exclusion criteria: * having vision and hearing problems * being 76 or older * having a neuro-psychiatric disease

Keywords: elderly self management chronic disease
the effectiveness of cow's milk immune globulin in the treatment of aids-related diarrhea

Conditions: Cryptosporidiosis; HIV Infections

Summary: to examine the efficacy of cow's milk immune globulin in the treatment of diarrhea due to chronic intestinal cryptosporidiosis in patients with aids. the secondary end points of the study involve functional improvement which will be determined from nutritional and absorption studies.


Eligibility criteria:
inclusion criteria patients must have: * diagnosis of diarrhea associated with intestinal cryptosporidiosis. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * survival time projected to be \< 9 weeks. * inability to tolerate any oral intake. * known allergy or intolerance to milk products. * organic mental syndrome precluding informed consent or following directions. patients with the following are excluded: * survival time projected to be \< 9 weeks. * inability to tolerate any oral intake. * known allergy or intolerance to milk products. * organic mental syndrome precluding informed consent or following directions.
genetic and risk factors in exfoliation glaucoma patients

Conditions: Glaucoma Capsulare; Genetic Predisposition to Disease; Risk Reduction

Summary: prospective non-randomised cohort study enrolling patients with exfoliation glaucoma. all patients were ophthalmological examined at inclusion. blood samples were taken for genetic analysis.

patients \& examinations in this prospective non-randomised cohort study, the investigators enrolled patients with exfoliation glaucoma at the ophthalmology department of the skaraborg's hospital, skövde, and sahlgrenska university hospital, gothenburg, from 1st january, 2014, to 31st december, 2017. all patients were followed-up for three years ± three months. informed consent was obtained from all patients. the study protocol was granted ethical approval by the university of gothenburg (dn:119-12). the study was performed in accordance with the tenets of the declaration of helsinki. at the recruiting visit, an ophthalmic nurse checked the visual acuity of patients with a snellen's chart and performed a visual field test. humphrey field analysis was performed using the software threshold 24-2. subsequently, an ophthalmologist measured the intracoular pressure (iop) with a goldmann applanation tonometer and performed slit-lamp biomicroscopy, including gonioscopy. pupils were then dilated with 2.5% phenylephrine and 0.5% tropicamide. after 20 min, the presence of exfoliation was confirmed, and the optic nerve was assessed using a 90-d lens. subsequently, the central corneal thickness (cct) was measured using an ultrasound device. the average value of seven measurements was automatically calculated. at the end of the visit, blood samples were collected. the number of medicines was registered as the number of compounds and not the number of bottles used.

Eligibility criteria:
inclusion criteria: * a diagnosis of exfoliation glaucoma based on the criteria established by the european glaucoma society terminology and guidelines for glaucoma, i.e., an untreated iop of ≥21 mmhg, an open anterior chamber angle, glaucomatous visual field defects (at least two repeatable humphrey 24-2 tests), glaucomatous optic nerve damage, and the presence of exfoliation material. * patients must performed at least five reliable visual field tests during the 3-year follow-up, with reliability defined as false positives ≤15%, false negatives ≤20%, and/or fixation losses ≤30%. * age ≤85 years at the recruiting visit. exclusion criteria: * a diagnosis of advanced glaucoma defined as mean deviation (md) ≥18 decibel (db) and/or visual field index (vfi) ≤40% because of 'floor effects,' in which further loss of visual field defects can no longer be detected. * history of glaucoma surgery other than uneventful cataract surgery or selective laser trabeculoplasty (slt). * other eye diseases (central venous occlusion, retinal detachment, etc.) that could affect the visual fields during the 3-year follow-up.

Keywords: glaucoma exfoliation risk factors genetics
extending cpap therapy in stable preterm infants to increase lung growth and function

Conditions: Neonatal; Premature Birth; Respiratory Distress Syndrome

Summary: this is a study to see if an extra 2 weeks of continuous positive airway pressure (cpap) in stable preterm infants in the neonatal intensive care unit (nicu) can cause increased lung growth and lung function in the infants as measured at 6 months of age by pulmonary function testing.

this is a study to see if an extra 2 weeks of continuous positive airway pressure (cpap) in stable preterm infants in the neonatal intensive care unit (nicu) can cause increased lung growth and lung function in the infants as measured at 6 months of age by pulmonary function testing. cpap is a treatment widely used in the nicu in preterm infants right after they are born to help keep their lungs open/inflated. although the benefit of cpap after birth has been well studied, no one knows how long a stable preterm infant should stay on cpap. the primary outcome of this study is to compare the lung volumes in the infants at 6 months of age by pulmonary function testing who were randomized to 2 extra weeks of cpap in the nicu versus cpap discontinuation, usual care. during the same pulmonary function test the investigators will also measure and compare how the infant's lungs diffuse gas.

Eligibility criteria:
inclusion criteria: 1. infants born at \>24 to ≤ 32 weeks gestation 2. treated with cpap for ≥ 24 hours for respiratory distress (either as initial therapy or following extubation) exclusion criteria: 1. significant congenital heart disease 2. major malformations 3. chromosomal anomalies 4. culture proven sepsis at consent 5. complex maternal medical conditions 6. clinical instability 7. multiple gestations \> twins 8. \ 97th percentile for weight85 9. participating in another neonatal randomized clinical trial with a competing outcome 10. mother/legal guardian without stable method of communication
feasibility of providing a purpose renewal intervention for cancer survivors via virtual groups

Conditions: Breast Cancer; Breast Neoplasm

Summary: the compass course (cc) is a group intervention designed for individuals with breast cancer. over the course of 8 face-to-face group sessions, the cc is designed to help participants reclaim a sense of self-grounded purpose in daily life, defined as intentional use of time and energy in ways that align with one's values, strengths, and sources of personal meaning (e.g., inner compass) in the moments that compose a day. because of covid-19, in-person groups are discouraged and so we need to identify new ways to provide group-based interventions that are feasible and efficacious.


Eligibility criteria:
inclusion criteria: 1. able to attend intervention sessions for 9 weeks on monday or tuesday afternoons (4:30 - 6:30 pm) starting monday, april 5, 2021 2. 25 years of age or older 3. completed chemotherapy and/or radiation treatment for stage 0, 1, 2, or 3 breast cancer at least 2 months prior to participating in the compass course intervention 4. english speaking 5. graduated from high school 6. able to see, hear, speak (with or without assistive devices) 7. able to provide own transportation to sessions 8. willing and able to commit to attend all 8 intervention sessions 9. access to computer or tablet and adequate internet connection to participate in video conference exclusion criteria: 1. stage 4 breast cancer or any other cancer 2. actively receiving chemotherapy or radiation treatments for cancer. (however, patients may be on herceptin and/or endocrine treatment and participate in the study.) 3. history of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning 4. any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.

Keywords: purpose
china post-market study of the incraft® aaa stent graft system in subjects with abdominal aortic aneurysms (initiation)

Conditions: Abdominal Aortic Aneurysms

Summary: initiation is a postmarket clinical follow-up study in china. the purpose of the study is to continue to evaluate the safety and effectiveness/performance of incraft in subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical practice. approximately 120 subjects will be enrolled and followed through 1-years postprocedure. up to 20 sites in china may participate.

initiation is a postmarket clinical follow-up study in china. the purpose of the study is to continue to evaluate the safety and effectiveness/performance of incraft in subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical practice. approximately 120 subjects will be enrolled and followed through 1-years postprocedure. up to 20 sites in china may participate. subjects will be enrolled and followed at 1 month and 1 year post-procedure.

Eligibility criteria:
inclusion criteria: * male or female aged 18 and over * the femoral access vessel is adequate for the selected delivery system; * length of proximal aneurysmal neck ≥ 10mm; * aortic neck diameter ≥ 17mm and ≤ 31mm; * the aortic neck is suitable for suprarenal fixation; * the angle of the infrarenal and suprarenal neck is ≤60 degrees; * iliac fixation length ≥ 15mm; * iliac diameter ≥ 7mm and ≤ 22mm; * minimum total aaa treatment length (proximal landing point to distal landing point) ≥ 128mm; * morphology is suitable for aneurysm repair; * written informed consent form shall be provided prior to initiating any study protocol; * the subject is willing to follow the prescribed follow-up schedule. exclusion criteria: * the subject has one of the following conditions: 1. aneurysm sac rupture or leaking abdominal aortic aneurysm 2. mycotic, dissecting, or inflammatory abdominal aortic aneurysm; * known to be allergic or intolerant to nickel titanium (nitinol), polyethylene terephthalate (pet) or polytetrafluoroethylene (ptfe); * known contraindication to undergoing angiography or anticoagulation * existing aaa surgical graft and/or a aaa stent-graft system; * women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the trial;
trabeculectomy with subconjunctival bevacizumab injection

Conditions: Glaucoma

Summary: the purpose of this study is to investigate the safety and efficacy of bevacizumab as an adjunctive treatment to trabeculectomy in open angle glaucoma patients and to compare this new drug to the most commonly used anti-scarring agent, mitomycin c.

the most common surgical technique for controlling the intraocular pressure in glaucoma patients is trabeculectomy.in this surgery, internal cavity of the eye is connected by a fistula like openings to subconjunctival space. the main cause of failure in trabeculectomy is excessive postoperative conjunctival scarring at the site of fistula, which is related to severity of conjunctival vascularization, tortuousity of vessel, and fibroblast migration and proliferation. at the time of surgery most surgeons use mitomycin c, which is an antimitotic and antifibrotic agent, to improve the results of the procedure. although this agent is very effective, but is not without complication. the most significant and sight threatening complications are low intraocular pressure and endophthalmitis. therefore investigations are going on to find a much safer and effective agents. bevacizumab is a monoclonal antibody against vascular endothelial factor (vegf). vegf is an important vasculogenic and fibrogenic factor with a prominent role in wound healing.bevacizumab is widely used in ophthalmology and has a promising effect in treatment of neovascularization in conjunctiva, cornea and retina. there are limited animal and human case series regarding the effect of this agent in trabeculectomy. in this study the investigators are trying, in addition to evaluating the efficacy and safety of this agent in result of trabeculectomy, compare this agent with mitomycin c.

Eligibility criteria:
inclusion criteria: * uncontrolled open angle glaucoma. * glaucoma patients who are non-compliant to medical treatment. * progressive glaucoma despite of medical treatment. * follow-up of at least 6 months after surgery exclusion criteria: * history of prior ocular surgery. * pregnancy or breast feeding. * age \< 18 years. * history of ocular surface infection in recent two weeks. * history of systemic thrombo-embolic events.

Keywords: intraocular pressure trabeculectomy mitomycin c bevacizumab
prevention of west syndrome with low-dose adrenocorticotropin hormone (acth)

Conditions: West Syndrome

Summary: west syndrome (ws) is a specific type of epilepsy (or seizure disorder) that has three features: infantile spasms (type of seizure), loss of milestones, and a specific pattern on electroencephalogram (eeg or brain wave test) called hypsarhythmia. the purpose of this study is to detect pre-hypsarhythmia in infants at high-risk for ws and determine whether treatment with acth will prevent ws.

hypothesis: preemptive acth will halt the evolution of hypsarhythmia and improve the eeg patterns in infants with pre-hypsarhythmic eeg. aim. to determine whether a low dose acth improves eeg, we will repeat eeg one month after a 2 week course of daily acth.

Eligibility criteria:
inclusion criteria: * infants with pre-hypsarhythmia (type 3 eeg) between 2 months to 12 months of age. exclusion criteria: * infants with any of the following diagnoses: * a previous history of infantile spasms; * known inborn error of metabolism; * other symptomatic epileptic encephalopathy (e.g. ohtahara syndrome).

Keywords: hypsarrhythmia spasms, infantile west syndrome
microfracture at proximal humerus lateral to footprint could enhance the rotator cuff healing

Conditions: Rotator Cuff Tears; Micro Fracture

Summary: the goal of this clinical trial is to test whether there is any effect on rotator cuff healing by making microfracture at the lateral side of the footprint. the main question it aims to answer are: * \[whether the lateralized microfracture could decrease the retear rate after arthroscopy rotator cuff repair.\] * \[whether the lateralized microfracture could improve the functional recovery after arthroscopy rotator cuff repair.\] participants with medium to larger size rotator cuff tears will be randomly assigned to the study group treated with lateralized microfracture immediately after arthroscopy rotator cuff repair or the control group treated with conventional arthroscopy rotator cuff repair without microfracture.


Eligibility criteria:
inclusion criteria: 1. medium to large rotator cuff tear(1cm-5cm) diagnosed by mri 2. patients can complete the follow-up and comply with all post-operative rehab instructions 3. failure of non-operative treatment for at least 3 months exclusion criteria: 1. revision rotator cuff surgery 2. partial thickness rotator cuff tears 3. small (less than 1cm) and massive (greater than 5cm) rotator cuff tears 4. disease history of the affected shoulder 5. systemic immune diseases 6. irreparable rotator cuff tear

Keywords: rotator cuff tear microfracture
feasibility of the implementation of tools for heart failure risk prediction

Conditions: Heart Failure; Cardiovascular Risk Factor

Summary: the purpose of this study is to gather information to develop a heart failure screening and prevention program.

all participants will undergo phlebotomy for specimen collection (bnp, hs-ctn, bmp and lipid testing, biorepository storage) and baseline echocardiography. all participants will additionally be administered a health and lifestyle questionnaire, undergo measurement of vital signs, and receive uniform education on heart-healthy lifestyle and signs and symptoms of heart failure. participants who are randomized to the intervention arm will receive a referral to heart failure prevention clinic, a pharmacist-directed practice in collaboration with an attending cardiologist, where they will be followed for 1 year, with their primary care physician updated after each visit. the information from their bnp, hs-ctn, and echocardiography will be provided to them and their primary care physicians as well as the pharmacist and cardiologist team members. the participants (and their primary care providers) who are randomized to usual care will be blinded to their bnp and hs-ctn values and echocardiography results.

Eligibility criteria:
inclusion criteria: * 10-year risk of heart failure \>5% based on the pcp-hf equations * at least one primary care visit in the last 12 months * at least one additional primary care visit in the last 5 years * had cholesterol and glucose checked within the past 5 years exclusion criteria: * history of cardiovascular disease * signs and symptoms of heart failure * estimated glomerular filtration rate \<45 ml/min/1.73m\^2 * stage 3 or 4 cancer * pregnancy
ultrasonographic measurements of the achilles tendon and talar condylar cartilage thickness in paraplegia patients.

Conditions: Paraplegia

Summary: investigators aim to measure the ankle talar cartilage and achilles tendon thicknesses ultrasonographically in paraplegic patients and compare them with the normal population.

paraplegia is a clinical condition that expresses the loss of motor and sensory function in the lower extremities after spinal cord injury. a specialized and intensive rehabilitation program is needed in these patient groups who develop immobilization. in healthy individuals, there is a certain biomechanics of the lower extremity. in paraplegic patients, this biomechanics changes due to weakness in the lower extremities. these biomechanical changes can cause different loads and effects on the lower extremity joints, muscles, tendons, and articular cartilages of paraplegic patients. among the rehabilitation goals of paraplegic patients, it is to stand up and walk the patient with or without support, with or without a device. during this rehabilitation, the position and function of the ankle is important. in this process, the talar condylar cartilage and achilles tendon forming the ankle joint can be exposed to different loads. ultrasonography is frequently used in physical therapy practice because it does not contain any radiation, has no side effects to the patient, facilitates dynamic and real-time evaluation of joint and muscle conditions and functions, and provides guidance during interventional procedure planning. in this study, investigators aim to ultrasonographically measure ankle talar cartilage and achilles tendon thicknesses in paraplegic patients with long-term immobilization and compare them with the normal population. our study will be organized as a observational study. it is planned to include 20 paraplegia patients and 20 healthy volunteers in the study. demographic data of the patients and healthy volunteers will be recorded. paraplegia patients will be evaluated in terms of barthel index, modified ashworth scale, american spinal injury association (asia) scale, walking index for spinal cord injury scale (wiscii-2).

Eligibility criteria:
inclusion criteria: * patients who are paraplegic after traumatic spinal cord injury (asia a-d) * healthy volunteers older than 18 years for control patients. exclusion criteria: * patients who had a previous trauma-related operation on the ankle. * patients who had fixed contracture or severe spasticity on the ankle. * patients who had lower-limb length difference of more than 2 cm.